Q-omics provides the consensus-scored DNAJB5-DT profile across patient tissues and cancer cell-line models. DNAJB5-DT expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, DNAJB5-DT is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, DNAJB5-DT RNA expression shows 7,954 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, KIRC, and UVM as cancer lineages where DNAJB5-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAJB5-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAJB5-DT survival associations across molecular data types. DNAJB5-DT RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAJB5-DT RNA expression–survival associations across cancer types. High DNAJB5-DT expression shows unfavorable associations in LUAD, ACC, THCA, UVM and PRAD, but favorable associations in COAD. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for DNAJB5-DT RNA expression.
This table summarizes DNAJB5-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DNAJB5-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAJB5-DT shows lower tumor expression in THCA and KICH and higher tumor expression in KIRC, HNSC, UCEC and LIHC. The KIRC box plot shows higher DNAJB5-DT RNA expression in tumor versus normal tissue (log2 FC = +0.317, t-test p < 0.001).
This table shows molecular features associated with DNAJB5-DT in patient tissues and cancer cell lines. In patient samples, DNAJB5-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
